Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multiple-treatments network meta-analysis
- PMID: 32247246
- DOI: 10.1016/j.critrevonc.2020.102944
Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: A multiple-treatments network meta-analysis
Abstract
Background: Graft-versus-host disease (GVHD) is a leading cause of death in patients after hematopoietic stem-cell transplantation (HSCT). Previous studies have shown different efficacy of GVHD prophylaxis therapies.
Methods: We reviewed 46 randomized controlled trials (including 8050 participants) systematically from Jun 20, 2004 to Aug 20, 2019. These investigations compared the following drugs or their combination at therapeutic dose range for GVHD after HSCT. The main results were based on the proportion of patients who respond to these therapies.
Results: Cyclosporine + methotrexate + Anti-T cell globulin (ATG), tacrolimus + methotrexate + ATG, tacrolimus + bortezomib + sirolimus and cyclosporine + marrow mesenchymal stem cells (MMSCs) were significantly more efficacious than corticosteroids alone (OR: 12.15, 6.71, 6.25, 3.73). corticosteroids alone were less efficacious than all the other GVHD prophylaxis therapies tested.
Conclusion: Cyclosporine + methotrexate + ATG may be the best choice when starting treatment for GVHD.
Keywords: Graft-versus-host disease; Hematopoietic stem-cell transplantation; Network meta-analysis; Prophylaxis.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare no competing financial interests.
Similar articles
-
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2023 Jun 21;6:CD009159. doi: 10.1002/14651858.CD009159.pub3. PMID: 22972135 Updated.
-
Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.Crit Rev Oncol Hematol. 2013 Oct;88(1):178-86. doi: 10.1016/j.critrevonc.2013.03.009. Epub 2013 Apr 2. Crit Rev Oncol Hematol. 2013. PMID: 23561334
-
Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.PLoS One. 2014 Dec 8;9(12):e114735. doi: 10.1371/journal.pone.0114735. eCollection 2014. PLoS One. 2014. PMID: 25485632 Free PMC article.
-
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.Cochrane Database Syst Rev. 2023 Jun 21;6(6):CD009159. doi: 10.1002/14651858.CD009159.pub3. Cochrane Database Syst Rev. 2023. PMID: 37341189 Free PMC article.
-
Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimus-based post-transplant cyclophosphamide (Methods of T cell Depletion, MoTD trial).BMJ Open. 2025 Jan 28;15(1):e086223. doi: 10.1136/bmjopen-2024-086223. BMJ Open. 2025. PMID: 39880444 Free PMC article.
Cited by
-
Comparison of ATG-thymoglobulin with atg-fresenius in patients with hematological malignancies who undergo allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis.Ann Hematol. 2025 Mar;104(3):1907-1916. doi: 10.1007/s00277-025-06267-4. Epub 2025 Feb 28. Ann Hematol. 2025. PMID: 40016396 Free PMC article.
-
GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party.Leukemia. 2025 Jun;39(6):1503-1511. doi: 10.1038/s41375-025-02619-1. Epub 2025 Apr 17. Leukemia. 2025. PMID: 40247107 Free PMC article.
-
Tacrolimus: Physicochemical stability challenges, analytical methods, and new formulations.Int J Pharm X. 2024 Sep 15;8:100285. doi: 10.1016/j.ijpx.2024.100285. eCollection 2024 Dec. Int J Pharm X. 2024. PMID: 39328187 Free PMC article. Review.
-
Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer-What Can We Learn from the Hematological Experience?Cancers (Basel). 2020 Jul 19;12(7):1966. doi: 10.3390/cancers12071966. Cancers (Basel). 2020. PMID: 32707721 Free PMC article. Review.
-
Impact of Low-Dose rATG Prior to Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Reduced Risk of Chronic Graft-versus-Host Disease and Improved Survival Outcomes.Cancer Manag Res. 2020 Nov 30;12:12287-12300. doi: 10.2147/CMAR.S283855. eCollection 2020. Cancer Manag Res. 2020. PMID: 33311999 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous